Skip to content
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN
SideMenu
Home
Fact Sheet
Biosimilars Council Press Releases
Fact Sheet
Fact Sheet
February 28, 2023
AAM
AAM Opposes HF17 and SF168 Which Won’t Bring Down Drug Prices for Minnesota Patients
Fact Sheet
October 13, 2022
AAM
How to Talk to Voters About the High Cost of Medicines and Ways to Lower Them
Fact Sheet
June 8, 2022
AAM
The Hatch-Waxman 180-Day Exclusivity Incentive Accelerates Patient Access to First Generics
Fact Sheet
April 26, 2022
AAM
Veto Illinois HB 1780 Which Puts Patient Access to Generic Medicines at Risk
Fact Sheet
February 4, 2022
AAM
Cancer Patients Save $16 Billion Per Year with Generics and Biosimilars
Fact Sheet
January 31, 2022
AAM
GDUFA Reauthorization: A Primer
Fact Sheet
January 31, 2022
AAM
BsUFA Reauthorization: A Primer
Fact Sheet
January 31, 2022
AAM
The Generic Drug User Fee Amendments (GDUFA III)
Fact Sheet
January 13, 2022
AAM
Generics and Biosimilar Medicines Deliver More Savings Every Year
Fact Sheet
March 31, 2021
AAM
Oppose Oregon SB 764
Fact Sheet
January 14, 2021
AAM
AAM Issue Brief: Biosimilars Medicare Part B
Fact Sheet
December 15, 2020
AAM
Letter from AAM: Mr. President, Block the BLOCKING Act!
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN